Circulating High-risk HPV Genotypes in the South of Benin and Disparity with General Immunization Target

Marie-Marthe A. Chabi^{1, 2,} , Callinice D. Capo-Chichi^{1, 2}, Théodora M. Zohoncon³, Christine Aguemon⁴, Ambaliou Sanni^{1, 2} and Jacques Simpore³

¹Department of Biochemistry and cell Biology / Team of Molecular Biomarker in Cancer and Nutrition (BMCN), Faculty of Sciences and Technics (FAST), University of Abomey Calavi (UAC), Abomey Calavi, Benin

²Department of Biochemistry and Molecular Biology / Team of Molecular Biomarkers in Cancer and Nutrition (BMCN), Institute of Biomedical Sciences and Applications (ISBA), Cotonou, Benin

³Department of Molecular Biology and Genetic LABIOGENE; “Pietro Annigoni Center for Biomolecular Research CERBA”, University of Ouagadougou, Ouagadougou, Burkina Faso

⁴Department of Gynecology and Obstetrics, National University Hospital (CNHU-HKM), Cotonou, Benin

Cite this paper:
Marie-Marthe A. Chabi, Callinice D. Capo-Chichi, Théodora M. Zohoncon, Christine Aguemon, Ambaliou Sanni and Jacques Simpore. Circulating High-risk HPV Genotypes in the South of Benin and Disparity with General Immunization Target. American Journal of Epidemiology and Infectious Disease. 2019; 7(1):16-24. doi: 10.12691/ajeid-7-1-4

Abstract

Background High-Risk Oncogenic Human Papillomaviruses (HR-HPV) are accountable for 7.7% of cancers in developing countries, mainly cervical lesions. In Benin, HR-HPV infection in women triggered nearly 781 new cases of cervical cancer each year leading to 616 (79%) deaths. Current vaccines may not cover all HR-HPV genotypes encountered in West Africa including Benin. The objective of our study was to determine HR-HPV genotypes in the South of Benin to launch regional HPV mapping associated to cervical lesions. For this purpose, HR-HPV genotypes from 2017 was compared to HPV genotypes from 2007 in the south of Benin to evaluate HR-HPV trend over a decade along with associated cervical lesions. Methods: regardless of technical methods, retrospective comparative analysis was done on HR-HPV genotypes of cervical uterine swab (CUS) samples in 2017 (n= 234) and 2007 (n=385). In 2017 real-time multiplexed PCR was used while in 2007-traditional nested polymerase chain reaction (PCR) was used. In both cases screening of cervical precancerous and cancerous lesions (dysplasia) was performed by colposcopy subsequently to vaginal application of acetic acid (VIA) and Lugol’s iodine solution (VILI). Statistical analysis was done with Pearson chi2 (χ²) test proportions and Student test. The difference was considered statistically significant for p <0.05. Results: The prevalence of HPV infected women in 2017 was 34% with 30 co-infections. Overall HR-HPV count was 125 with high frequency for HPV52 (16%), HPV58 (10%), HPV51 (9%), HPV66 (8%), HPV68 (8%), HPV35 (8%) and HPV45 (8%). The least frequent genotypes were HPV18 (6%), HPV16 (1.6%) and HPV33 (1.6%). Positive VIA and VILI were observed respectively in 5.55% (13/234) and 6.83% (16/234) women. In 2007 the prevalence of HR-HPV was 22.07% with 18 co-infections. Common HR-HPV genotypes found were HPV 35 (14.28%), HPV31 (13.33%), HPV66 (13.33%), HPV68 (13.33%), HPV58 (10.47%), HPV52 (8.57%), HPV51 (7.61%), HPV18 (6.66%), HPV45 (5.71%), HPV16 (3.80%) and HPV33 (3.80%). No correlation was observed between HR-HPV and cervical lesions. Conclusion: HR-HPV infection keep rising over a decade in the south of Benin with noticeable disparity with cervical lesions. Regional HR-HPV trend should be investigated prior to large scale vaccination for cervical cancer prevention in Africa.

Keywords:
Oncogenic HPV genotypes vaccine targets cervical lesions disparity south of Benin

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Alain S, Hantz S, Denis F. Papillomavirus: les virus et la physiopathologie de l’infection [Papillomavirus: Virus and Pathophysiology of Infection]. Médecine Thérapeutique / Pédiatrie, 13 (1): 5-19, Feb 2010.
[2]	WHO. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, 92 (19): 241-268, May 2017.
[3]	WHO. Comprehensive cervical cancer control. A guide to essential practice. 2nd ed. 2017.
[4]	Mboumba Bouassa RS, Prazuck T, Lethu T, Meye JF, Bélec L. Cervical Cancer in Sub-Saharan Africa: An Emerging and Preventable Disease Associated with Oncogenic Human Papillomavirus. Médecine et Santé Tropicales, 27 (1): 16-22, 2017.
[5]	Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human Papillomavirus and Related Diseases in Benin. ICO Information Center on HPV and Cancer (HPV Information Centre), 2017.
[6]	Yi Yang D, and Bracken K. Mise à jour sur le nouveau vaccin 9-valent pour la prévention du virus du papillome humain. Canadian Family Physician. 2016; 62: 236-240.
[7]	Ouattara A, Yeo A, Blavo-Kouame EB, Koffi TF, Saraka D, Oura PK, Faye-Kette H, Dosso M. Detection of Cervical Human Papillomavirus in Women Attending for Cervical Cancer Screening by Visual Inspection in Côte d’Ivoire.” Journal of Cancer Research and Experimental Oncology. 9(3): 7-15, 2017.
[8]	Zohoncon TM, Bisseye C, Djigma FW, Yonli AT, Compaore TR, Sagna Tani, Ouermi Djeneba, Ouédraogo CMR, Pietra V, Nikiéma J-B, Akpona SA, Simpore Jacques. Prevalence of HPV High-Risk Genotypes in Three Cohorts of Women in Ouagadougou (Burkina Faso). Mediterranean Journal of Hematology and Infectious Diseases, 5 (1): 1-6, 2013.
[9]	Herrera-Ortiz A, Carlos JC-G, Olamendi-Portugal ML, García-Cisneros S, Plett-Torres T, Sánchez-Alemán MA. College Women, HPV Genotyping and Sexual Behavior before HPV Vaccination: Results from Samples Stored for a Long Time.” Journal of Infection and Public Health, 826: 8-11, 2017.
[10]	Fogue P, Djeudong G, Bouting G, Aglago E, Simo G, Lueong S. Molecular Characterization of Lower Vaginal Swabs for Human Papilloma Virus in Association with Chlamydia Trachomatis Infection in Cameroonian Women. Journal of Infection and Public Health,. 11: 314-320, 2017.
[11]	Catarino R,Vassilakos P, Jinoro J, Broquet C, Benski A-C, Meyer-Hamme U, Petignat P. Human Papillomavirus Prevalence and Type-Specific Distribution of High- and Low-Risk Genotypes among Malagasy Women Living in Urban and Rural Areas. Cancer Epidemiology, 42: 159-166, 2016.
[12]	Catarino R, Vassilakos P, Tebeu P-M, Schäfer S, Bongoe A, Petignat P. Risk Factors Associated with Human Papillomavirus Prevalence and Cervical Neoplasia among Cameroonian Women. Cancer Epidemiology, 40: 60-66, Feb 2016.
[13]	Traore IMA, Zohoncon TM, Ndo O, Djigma FW, Obiri-Yeboah D, Compaore TR, Guigma SP. Oncogenic Human Papillomavirus Infection and Genotype Characterization among Women in Orodara , Western Burkina Faso. Pakistan Journal of Biological Sciences, 19: 306-311, 2016.
[14]	Ouhoummane N, Goggin P, Louchin R. Les infections au Virus du Papillome Humain (VPH) et le portrait des cancers associés à ces infections au québec. Institut national de santé publique du quebec,1709:1-105, 2013.
[15]	Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. “Chapter 1: HPV in the Etiology of Human Cancer.” Vaccine, 24(3): 1-10, 2006.
[16]	Ogembo RK, Gona PN, Seymour AJ, Soo-Min Park H, Bain PA, Maranda L, Ogembo JG. Prevalence of Human Papillomavirus Genotypes among African Women with Normal Cervical Cytology and Neoplasia: A Systematic Review and Meta-Analysis. Plos One, 10 (4): e0122488, 2015.
[17]	Traore IMA, Zohoncon TM, Dembele A, Djigma FW, Obiri-Yeboah D, Traore G, Bambara M, Ouedraogo C, Traore Y, Simpore J. Molecular Characterization of High-Risk Human Papillomavirus in Women in Bobo-Dioulasso, Burkina Faso. BioMed Research International,7: 7092583, Jul 2016.
[18]	Capo-chichi CD, Aguida B, Chabi NW, Acapko-Ezin J, Sossah-Hiffo J, Agossou VK, Anagbla T, Zannou M, Houngbé F, Sanni A. Diversity of High Risk Human Papilloma Viruses in Women Treated with Antiretroviral and in Healthy Controls and Discordance with Cervical Dysplasia in the South of Benin. Infectious Agents and Cancer, 11(1): 43, 2016.
[19]	Capo-chichi CD, Aguida B, Qi Cai K, Offrin G, Agossou VK, Sanni A, Xiang-xi X. The Deficiency of Nuclear Proteins GATA6 and Lamin A / C as Prognostic Factor for Cervical Neoplasia. American Journal of Cancer Prevention, 3(6): 109-116, 2015.
[20]	Capo-chichi CD, Aguida B, Chabi NW, Qi Cai K, Offrin G, Agossou VK, Sanni A, Xiang-Xi X. Lamin A/C Deficiency Is an Independent Risk Factor for Cervical Cancer. Cellular Oncology (Dordrecht), 39: 59-68, Feb 2016.
[21]	Broers JLV, Ramaekers FCS. The Role of the Nuclear Lamina in Cancer and Apoptosis. Advances in Experimental Medicine and Biology, 773: 27-48, 2014.
[22]	Zohoncon TM, Ouédraogo TC, Brun LVC, Obiri-Yeboah D, Djigma FW, Kabibou S, Ouattara S, Gomina M,Yonli AT, Bazié VJTE, Ouédraogo C, Lompo O, Akpona SA, Simpore J. Molecular Epidemiology of High-Risk Human Papillomavirus in High-Grade Cervical Intraepithelial Neoplasia and in Cervical Cancer in Parakou, Republic of Benin. Pakistan Journal of Biological Sciences, 19(2): 49-56, 2016.
[23]	Baba-Moussa L, Akele-Akpo MT, Adjobimey T, Missihoun D T, Sanni A. What Do the Inflammatory Cervical Smears Hide? A Comparison of Cytopathology and PCR in Cotonou. Revue Africaine de Pathologie, 5(1) : 21-25,2006.
[24]	Piras F, Piga M, De Montis A, Zannou ARF, Minerba L, Perra MT, Murtas D, Atzori M, Pittau M, Maxia C, Sirigu P. Prevalence of human papillomavirus infection in women in Benin, West Africa. Virol J, 8: 514, Nov 2011.